Pruritus - Pipeline Insight, 2025: Novel Anti-itch Pathways Emerge as Biotech and Pharma Target Dermatologic and Systemic Origins | DelveInsight

Pruritus (chronic itch), a common symptom across dermatologic, hepatic, and renal conditions, is gaining recognition as a standalone therapeutic target. With existing treatments offering only symptomatic relief, the pruritus treatment pipeline is expanding rapidly to address both the sensory and inflammatory drivers of the condition.

DelveInsight's "Pruritus - Pipeline Insight, 2025" evaluates over 30+ active pipeline agents, including kappa opioid receptor agonists, IL-31 and JAK inhibitors, neurokinin-1 receptor antagonists, and other neuromodulatory therapies. Companies such as GlaxoSmithKline, Chugai Pharmaceutical, Regeneron/Sanofi, DiverDrugs, Atridia, Asana BioSciences, and others are pioneering innovation across pruritus subtypes, including uremic, cholestatic, and atopic dermatitis-associated pruritus.

The report offers in-depth insights into late-stage programs, trial designs, and biomarker-based patient stratification efforts. As the understanding of the neuroimmune axis of itch deepens, targeted and systemic approaches are being developed to achieve better efficacy and tolerability profiles.

The evolving landscape reflects a paradigm shift-treating pruritus not just as a symptom, but as a distinct therapeutic domain warranting focused and disease-specific interventions.

Interested in learning more about the current treatment landscape and the key drivers shaping the pruritis pipeline? Click here: https://www.delveinsight.com/sample-request/pruritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Pruritis Pipeline Report
• DelveInsight's Pruritis pipeline analysis depicts a strong space with 25+ active players working to develop 30+ pipeline drugs for Pruritis treatment.
• The leading Pruritis companies include GlaxoSmithKline, Chugai Pharmaceutical, Regeneron/Sanofi, DiverDrugs, Atridia, Asana BioSciences, Vanda Pharmaceuticals, Pfizer, Trevi Therapeutics, AbbVie, Lumosa Therapeutics, Luye Pharma Group, and others are evaluating their lead assets to improve the Pruritis treatment landscape.
• Key Pruritis pipeline therapies in various stages of development include Linerixibat, Nemolizumab, Dupilumab, Parentide, SHR 0410, ASN 008, Tradipitant, Abrocitinib, Nalbuphine extended release, Onabotulinum toxin A, LT 5001, BA 2101, and others.
• In May 2025, the FDA released a safety alert warning that patients stopping long-term use of prescription (and OTC) antihistamines cetirizine (Zyrtec) or levocetirizine (Xyzal) may experience rare but severe itching, also known as pruritus, appearing within days of discontinuation.
• In June 2025, the FDA has accepted GSK's New Drug Application (NDA) for linerixibat (IBAT inhibitor), targeting cholestatic pruritus in primary biliary cholangitis (PBC).
• In April 2025, the FDA approved a tablet formulation of maralixibat for cholestatic pruritus in patients with Alagille syndrome (ALGS) (≥3 months old) and PFIC (≥12 months old).

Request a sample and discover the recent breakthroughs happening in the pruritis pipeline landscape at https://www.delveinsight.com/sample-request/pruritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Pruritis Overview
Pruritus, or chronic itching, is a debilitating symptom linked to a variety of underlying conditions, including dermatological disorders, liver diseases, kidney dysfunction, and certain cancers. It significantly impacts patients' quality of life, often leading to sleep disturbances and psychological distress. While conventional treatments like antihistamines and corticosteroids offer relief for some, many cases-especially those related to systemic diseases like cholestatic or uremic pruritus-remain resistant. Recent FDA approvals, such as maralixibat and difelikefalin, along with promising agents like linerixibat and TH104 in clinical trials, are reshaping the pruritus treatment landscape. With increased research, innovation, and patient-focused therapies, the global pruritus market is set to expand, addressing long-standing unmet needs.

Find out more about pruritis medication at https://www.delveinsight.com/sample-request/pruritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Pruritis Treatment Analysis: Drug Profile
Linerixibat: GlaxoSmithKline
Linerixibat, developed by GlaxoSmithKline, is an investigational oral therapy being evaluated for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC). It functions as a minimally absorbed small-molecule inhibitor of the ileal bile acid transporter (IBAT), designed to lower circulating bile acids-key contributors to pruritus-by preventing their reabsorption in the small intestine. In 2019, the U.S. FDA granted orphan drug designation to linerixibat for the treatment of PBC-related pruritus, recognizing the urgent need for effective therapies in this underserved patient population.

Learn more about the novel and emerging pruritis pipeline therapies at https://www.delveinsight.com/sample-request/pruritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Pruritis Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intranasal
• Intrathecal
• Intravenous
• Oral
• Oral/Intravenous
• Parenteral
• Subcutaneous
• Subcutaneous/Intramuscular
• Transdermal

By Molecule Type
• Antisense oligonucleotide
• Gene therapy
• Hormones
• Neuropeptides
• Oligonucleotides
• Small Molecule
• Triglyceride

Scope of the Pruritis Pipeline Report
• Coverage: Global
• Key Pruritis Companies: GlaxoSmithKline, Chugai Pharmaceutical, Regeneron/Sanofi, DiverDrugs, Atridia, Asana BioSciences, Vanda Pharmaceuticals, Pfizer, Trevi Therapeutics, AbbVie, Lumosa Therapeutics, Luye Pharma Group, and others.
• Key Pruritis Pipeline Therapies: Linerixibat, Nemolizumab, Dupilumab, Parentide, SHR 0410, ASN 008, Tradipitant, Abrocitinib, Nalbuphine extended release, Onabotulinum toxin A, LT 5001, BA 2101, and others.

Dive deep into rich insights for drugs used for pruritis treatment, visit: https://www.delveinsight.com/sample-request/pruritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Pruritis Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Pruritis Pipeline Therapeutics
6. Pruritis Pipeline: Late-Stage Products (Phase III)
7. Pruritis Pipeline: Mid-Stage Products (Phase II)
8. Pruritis Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.